Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
All entries in neuroendocrine and adrenal tumors
- Trial result
Neuroendocrine and adrenal tumors
Single ¹³¹I-MIBG (NET-targeted radiopharmaceutical) + single autologous stem cell rescue shows feasible engraftment but low response in resistant neuroblastoma
¹³¹I-metaiodobenzylguanidine (¹³¹I-MIBG) is a norepinephrine transporter (NET)-avid targeted radiopharmaceutical for MIBG-avid neuroblastoma; this retrospective expanded-access experience (NCT00107289) at MSK…
NCT00107289 - Trial result Spotlight
Neuroendocrine and adrenal tumors
¹⁷⁷Lu-DOTATATE (SSTR-targeted PRRT) extends PFS ~14 months vs high-dose octreotide in 1L G2–G3 GEP-NETs
¹⁷⁷Lu-DOTATATE is a radiolabeled somatostatin analog (PRRT) that targets somatostatin receptor–positive (SSTR+) disease; in the open-label, randomized Phase 3 NETTER-2 trial (NCT03972488), previously untreated…
NCT03972488 - New trial
Neuroendocrine and adrenal tumors
Phase 2 ivonescimab PD-1×VEGF bispecific antibody in previously treated ACC/PPGL
This Phase 2, open-label, multi-cohort study at MD Anderson Cancer Center evaluates ivonescimab given intravenously every 3 weeks in two rare endocrine malignancy populations: unresectable/metastatic adrenocortical…
NCT07743138 Exploratory - Trial result Spotlight
Neuroendocrine and adrenal tumors
[177Lu]Lu-edotreotide (SSTR2-targeted PRRT) beats everolimus on PFS in progressive GEP-NETs (COMPETE)
[177Lu]Lu-edotreotide is a somatostatin receptor (SSTR; high affinity for SSTR2)–targeted peptide receptor radionuclide therapy (PRRT; [177LuDOTA]-TOC) compared head-to-head with everolimus (oral mTOR inhibitor) in…
NCT03049189 - New trial
Neuroendocrine and adrenal tumors
Phase 1 211At‑MABG targeted alpha radiotherapy (NET/norepinephrine transporter–avid) in advanced NETs
University of Pennsylvania is running a first-in-human Phase 1, open-label, single-group dose-escalation (standard 3+3) study with an RP2D expansion cohort to evaluate fractionated intravenous 211At‑MABG…
NCT07661420 First-in-human - Trial result Spotlight
Neuroendocrine and adrenal tumors
Sacituzumab govitecan (TROP2–SN-38 TOP1 ADC) + berzosertib (ATR inhibitor) lifts disease control to 86% in platinum-refractory EPSCC
Berzosertib is an IV ATR (replication-stress response) inhibitor combined here with either conventional TOP1 inhibition (topotecan) or tumor-targeted TOP1 payload delivery via the TROP2-directed ADC sacituzumab…
NCT03896503 - Trial result
Neuroendocrine and adrenal tumors
Cabozantinib (multi-kinase VEGFR/MET/AXL inhibitor) cuts progression risk in functional vs non-functional NET in CABINET
Cabozantinib (CABO) is an oral multi-target tyrosine kinase inhibitor (notably VEGFR2, MET, AXL) evaluated in the Phase 3 CABINET trial (NCT03375320) in progressive, previously treated advanced extrapancreatic NET…
NCT03375320 - Trial result
Neuroendocrine and adrenal tumors
Lu-177 Edotreotide Preserves QoL Better Than Everolimus in GEP-NETs
Lutetium Lu-177 edotreotide is an SSTR-targeted peptide receptor radionuclide therapy compared with everolimus in the Phase 3 COMPETE trial (NCT03049189) for grade 1/2 well-differentiated gastroenteropancreatic NETs.…
NCT03049189 - Trial result
Neuroendocrine and adrenal tumors
[212Pb]VMT-α-NET Shows 39% ORR With Low Early Myelosuppression in NETs
[212Pb]VMT-α-NET is an SSTR2-targeted alpha-particle radiopharmaceutical being dose-found in a Phase 1/2a Bayesian escalation trial for unresectable/metastatic well-differentiated SSTR2+ NETs after ≥1 prior systemic…
NCT05636618 - New trial
Neuroendocrine and adrenal tumors
Phase 2 AUR103 calcium oral CD47 antagonist tests innate-immunity reactivation in NETs.
This proof-of-concept, open-label Phase 2 study (BHARAT-3) evaluates single-agent AUR103 calcium—an orally bioavailable small-molecule CD47 antagonist that aims to block the “don’t-eat-me” signal and promote…
NCT07640737 Exploratory - New trial
Neuroendocrine and adrenal tumors
Phase 1 CIML-NK allogeneic NK-cell immunotherapy (IL-12/15/18–primed “memory-like” NK cells)
This first-in-human, single-site Phase 1 study at Cincinnati Children’s tests whether cytokine-induced memory-like natural killer cells (CIML-NK)—an allogeneic NK-cell product generated from a patient’s…
NCT07635056 First-in-human - New trial Spotlight
Neuroendocrine and adrenal tumors
Phase 3 obrixtamig DLL3×CD3 bispecific T‑cell engager plus platinum/etoposide in DLL3+ epNEC
Boehringer Ingelheim’s multicenter, open-label, randomized Phase 3 trial (NCT07544654) tests whether adding obrixtamig—an IgG-like DLL3×CD3 bispecific antibody that redirects T cells to kill DLL3-expressing tumor…
NCT07544654 Registrational - New trial
Neuroendocrine and adrenal tumors
Phase 1 RYZ401 Actinium-225 SSTR2-targeted alpha radiopharmaceutical in SSTR+ tumors.
This first-in-human Phase 1, open-label dose-escalation and dose-expansion trial tests RYZ401, RayzeBio’s somatostatin receptor (SSTR2)-targeted peptide radiopharmaceutical labeled with actinium-225, an…
NCT07165132 First-in-human - Trial result
Neuroendocrine and adrenal tumors
Peposertib (M3814) + DNA-PK Inhibition Sensitizes Lu-177 DOTATATE, Driving 21% ORR in Pre-treated SSTR+ GEP-NETs
Peposertib is an oral DNA-dependent protein kinase (DNA-PK) inhibitor designed to radiosensitize tumors by blocking nonhomologous end-joining DNA repair; here it was combined with Lu-177 DOTATATE peptide receptor…
NCT04750954 - Trial result
Neuroendocrine and adrenal tumors
[212Pb]VMT-α-NET (SSTR2-targeted alpha therapy) shows 39% ORR with clean early safety in PRRT-naïve NETs
[212Pb]VMT-α-NET is a SSTR2-targeted radiopharmaceutical that delivers the alpha-emitter lead-212 to SSTR2+ neuroendocrine tumors. In the Phase 1/2a dose-finding trial (NCT05636618) in well-differentiated…
NCT05636618 - Trial result
Neuroendocrine and adrenal tumors
ZL-1310 (DLL3-targeted topo-I ADC) drives 48% ORR in platinum-refractory extrapulmonary NEC (early Phase 1b)
ZL-1310 is a DLL3-targeted antibody–drug conjugate delivering a topoisomerase I inhibitor payload via a protease-cleavable linker (TMALIN® platform). In the Phase 1b/2 ZL-1310-002 study (NCT06885281), patients with…
NCT06885281 - New trial
Neuroendocrine and adrenal tumors
Phase I trial of [68Ga]Ga-FAPI-04, a fibroblast activation protein inhibitor for imaging.
This early phase I trial at University of Michigan Rogel Cancer Center evaluates the biodistribution and uptake of [68Ga]Ga-FAPI-04—a tracer that binds fibroblast activation protein—in patients with high-grade…
NCT07132645 Exploratory - New trial Spotlight
Neuroendocrine and adrenal tumors
Phase Ib/II ZL-1310: DLL3-targeted Topoisomerase I inhibitor in selected solid tumors.
This multi-center, open-label trial from Zai Lab (Shanghai) is assessing ZL-1310 as a single-agent therapy in patients with neuroendocrine carcinomas progressing after platinum therapy. The study is conducted at…
NCT06885281 Exploratory - New trial
Neuroendocrine and adrenal tumors
Phase 1 study of naxitamab GD2-directed monoclonal antibody in neuroblastoma
This trial uses a modified 3+3 design to assess the optimal naxitamab infusion duration with irinotecan, temozolomide, and sargramostim in patients with relapsed or refractory neuroblastoma or ganglioneuroblastoma.…
NCT07027748 Exploratory - New trial
Neuroendocrine and adrenal tumors
Phase 2/3 Zanzalintinib Trial: cMet/VEGFR inhibitor in Neuroendocrine Tumors
This multicenter, randomized open-label study sponsored by Exelixis compares daily oral zanzalintinib to everolimus in patients with previously treated, unresectable locally advanced or metastatic neuroendocrine…
NCT06943755 Exploratory - New trial
Neuroendocrine and adrenal tumors
Phase 1 trial of PHOX2B PC-CAR T, a PHOX2B-directed CAR-T therapy
This first-in-human dose escalation trial uses a standard 3+3 design to determine the maximum tolerated dose in patients with relapsed or refractory high‐risk neuroblastoma. The study, led by Stephan Grupp MD PhD in…
NCT07007117 First-in-human - New trial
Neuroendocrine and adrenal tumors
Phase 3 trial of [177Lu]Lu-DOTA-TATE, a somatostatin receptor-targeted radioligand therapy.
This study evaluates the efficacy and safety of [177Lu]Lu-DOTA-TATE plus octreotide LAR versus octreotide LAR alone as first-line treatment in newly diagnosed patients with well-differentiated, somatostatin receptor…
NCT06784752 Registrational - New trial
Neuroendocrine and adrenal tumors
Phase I trial of rhIL-15 immune agonist in relapsed/refractory neuroblastoma.
This study evaluates escalating IV doses of rhIL-15 combined with dinutuximab, irinotecan, and temozolomide administered in 21-day cycles. It enrolls children and young adults (ages 3–35) with relapsed or refractory…
NCT06995872 - Trial result
Neuroendocrine and adrenal tumors
Obrixtamig (DLL3/CD3 Engager) Achieves 40% ORR in DLL3-High Extrapulmonary NEC
Delta-like ligand 3 (DLL3) is highly expressed in neuroendocrine carcinomas (NEC). Obrixtamig (BI 764532) is a DLL3/CD3 IgG-like T-cell engager that targets DLL3-positive tumors. In a Phase I trial (NCT04429087),…
NCT04429087 - New trial
Neuroendocrine and adrenal tumors
18F-Fluorodopamine PET Studies of Neuroblastoma and Pheochromocytoma
This pilot study at St. Jude is evaluating the safety and biodistribution of 18F-DA in pediatric patients with neuroblastoma or pheochromocytoma, while comparing its imaging clarity with the current standard,…
NCT03541720 - New trial
Neuroendocrine and adrenal tumors
Zanzalintinib Maintenance in High Grade Neuroendocrine Neoplasms
Washington University School of Medicine is evaluating zanzalintinib as a maintenance therapy following initial chemotherapy to extend progression-free survival in patients with high-grade neuroendocrine neoplasms.…
NCT06926634
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.